Release Date: December 10, 2022
Expiration Date: February 1, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in MRD monitoring for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in MRD monitoring for patients with hematologic malignancies are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain best practices in the assessment of MRD across hematologic malignancies, including the techniques and platforms
- Determine guideline recommendations and expert consensus to inform the use of MRD monitoring in hematologic malignancies’ settings
- Analyze the role of MRD assessment when planning treatment across the continuum of care for hematologic malignancies
- Formulate plans to integrate emerging data, sampling techniques, MRD assessment, and clinical trial data into the management of patients with hematologic malignancies.

C. Ola Landgren, MD, PhD
Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Amgen; Celgene; Janssen; Takeda. Consultant: Adaptive Biotechnologies; Bristol Meyers Squibb; Celgene; GSK; Jansen; Karyopharm Therapeutics Inc; Merck; Pfizer Inc; Sanofi. Other: IDMC – AstraZeneca; Janssen; Merck; Takeda.

Paolo Ghia, MD
Professor, Medical Oncology
Università Vita Salute San Raffaele
Director, Strategic Research Program on CLL
IRCCS San Raffaele Scientific Institute
Milan, Italy
Disclosures: Grant/Research Support: AbbVie; AstraZeneca; Janssen; MSD. Consultant: AbbVie; AstraZeneca; Bristol Meyers Squibb; Janssen; Loxo Oncology/Lilly; MSD; Roche.

Aaron C. Logan MD, PhD
Associate Professor (Hematology, BMT, & Cellular Therapy)
University of California
San Francisco, CA
Disclosures: Grant/Research Support: Amgen; Astellas Pharma Inc; Autolus Therapeutics; Kadmon; Kite; Pharmacyclics. Consultant: AbbVie; Bristol Meyers Squibb; Pfizer Inc.

Reid W. Merryman, MD
Physician Dana-Farber Cancer Institute
Instructor in Medicine Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: Merck, Bristol Myers Squibb, Genmab, Genentech/Roche. Consultant: Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Inteillia, Epizyme, Alphasights
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here


